IsoRay, Inc. (ISR) Issues Earnings Results

IsoRay, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings results on Tuesday. The healthcare company reported ($0.03) EPS for the quarter, Bloomberg Earnings reports. IsoRay had a negative net margin of 135.40% and a negative return on equity of 65.23%.

Shares of IsoRay (NYSEAMERICAN:ISR) traded down $0.01 during midday trading on Wednesday, hitting $0.43. The company had a trading volume of 146,300 shares, compared to its average volume of 110,501. IsoRay has a 1 year low of $0.38 and a 1 year high of $0.70.

TRADEMARK VIOLATION WARNING: This piece was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at

Separately, Maxim Group restated a “buy” rating and set a $3.00 price target on shares of IsoRay in a report on Thursday, September 28th.

IsoRay Company Profile

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Earnings History for IsoRay (NYSEAMERICAN:ISR)

Receive News & Ratings for IsoRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply